A study presented at the San Antonio Breast Cancer Symposium showed promising results for combining a poly(ADP-ribose) polymerase inhibitor with a PD-1 antibody in a nonchemotherapy regimen for BRCA-mutated breast cancer. The study, led by Dr. Erica L. Mayer, included patients with BRCA1, BRCA2, and PALB2 mutations who achieved a pathologic complete response and residual cancer burden of zero or one after 18 weeks of targeted treatment. The results demonstrate the potential for nonchemotherapy and immunology-based approaches to effectively treat this subtype of breast cancer and are generating excitement within the medical community.
Source link
Combination treatment shows promise in BRCA -, PALB2 -mutated breast cancer
